Manmeet Ahluwalia

Jan 7, 2025 | targetedonc.com | Manmeet Ahluwalia

Manmeet Ahluwalia, MD, MBA, FASCO, chief scientific officer, chief of medical oncology, deputy director, and Fernandez Family endowed chair in cancer research at the Baptist Health Miami Cancer Institute, discusses the prevalence of brain metastases in patients with primary renal cell carcinoma (RCC).

Dec 19, 2024 | onclive.com | Manmeet Ahluwalia

Manmeet Singh Ahluwalia, MD, MBA, FASCO, discusses the phase 2b SURVIVE trial of SurVaxM plus chemoradiation in newly-diagnosed glioblastoma.

Dec 9, 2024 | nature.com | Ahmad Ozair |Nicholas Mikolajewicz |Stuart A Grossman |Arjun Sahgal |Emilie Le Rhun |Michael Weller | +12 more

AbstractLeptomeningeal metastatic disease (LMD), encompassing entities of ‘meningeal carcinomatosis’, neoplastic meningitis’ and ‘leukaemic/lymphomatous meningitis’, arises secondary to the metastatic dissemination of cancer cells from extracranial and certain intracranial malignancies into the leptomeninges and cerebrospinal fluid.

Aug 19, 2024 | targetedonc.com | Manmeet Ahluwalia

The NAVAL trial (NCT03452579) investigated the effectiveness of combining the immunotherapy nivolumab (Opdivo) with different doses of the anti-angiogenic therapy bevacizumab (Avastin) in treating recurrent glioblastoma (rGBM). Previous studies have shown limited success with immunotherapy alone for this aggressive brain cancer. The trial compared a standard dose and a lower dose of bevacizumab in combination with nivolumab.

Jul 1, 2024 | cell.com | Manmeet Ahluwalia |Ahmad Ozair |Johns Hopkins

Highlights • Multicenter, phase 1 trial of oral terameprocol for recurrent high-grade glioma • Drug well tolerated in 3 + 3 dose-escalation design, but bioavailability was poor (∼2%) • Higher oral doses in patients not associated with increased systemic exposure • Trials investigating sustained systemic levels of transcription inhibitors are needed Summary Recurrent high-grade gliomas (rHGGs) have a dismal prognosis, where the maximum tolerated dose (MTD) of IV terameprocol (5 days/month), a...